You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.

    SBC: TROPHOGEN INC            Topic: 102

    Thyroid cancer is the most common malignancy of endocrine tissues, disproportionally affecting women, and is one of the few cancers greatly increasing in incidence andamp; prevalence for unknown reasons. A very aggressive form of this cancer may result from nuclear accidents like Chernobyl andamp; Fukushima, increasing proximity of nuclear waste storage sites, or from nuclear explosions including ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression

    SBC: PRIMETIME LIFE SCIENCES, LLC            Topic: 101

    Depression is a common mental disorder, which can be chronic or recurrent, markedly tarnishing a person’s ability to function in their normal life. People with a depression can feel empty, sad, helpless, restless, hopeless, anxious, worthless, guilty, irritable, ashamed or suicidal. They may lose interest in routine work or physical activities. They show appetite disorder, problems concentrating ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery

    SBC: FANNIN PARTNERS LLC            Topic: NICHD

    PROJECT SUMMARY Of the 4 million babies born in the US each year, 120,000 (3%) have a complex birth defect. Some defects, such as spina bifida, warrant in utero interventions to improve fetal outcomes. Spina bifida is a condition where there is incomplete closing of the backbone and membranes around the spinal cord. Texas Children’s Hospital has pioneered a fetoscopic method to address spina bif ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.

    SBC: RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC            Topic: 101

    Project SummaryRadiopharmaceutical therapy (RPT) – the use of targeted radionuclides to deliver radiation specifically to cancer cells and their microenvironment – is a fundamentally different approach to cancer therapy that is growing, with a substantial number of large and small pharmaceuticals companies developing products in this area and radionuclide producers making substantial investmen ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Towards virtual laboratory for optimizing cardiac rhythm

    SBC: CARDIOSOLV ABLATION TECHNOLOGIES, INC.            Topic: NHLBI

    PROJECT SUMMARY CardioSolv Ablation Technologies, Inc. has developed and aims to commercialize a simulation-based approach for non-invasive prediction of the optimal targets of catheter ablation in patients with infarct- related ventricular tachycardia. Successful completion of the commercialization will result in a major paradigm shift in the clinical procedure of ventricular tachycardia ablation ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Automated 3D Ultrasound-based Surveillance of Arteriovenous Fistula Maturation for Post-operative Hemodialysis Patients

    SBC: SONAVEX INC            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Severe kidney disease accounts for 7% of all Medicare and Medicaid costs. The most cost-effective way to perform dialysis uses an arteriovenous fistula to connect to dialysis machines, but fistula use is limited by the malfunctions immediately following creation (maturation failure), which can render up to 70% of all created fistulas unusable. Ultrasound monitoring of the ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical Development of OCF001 for Treatment of Yeast Infections

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of VLP vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Respiratory syncytial virus (RSV) is a significant human pathogen severely impacting neonates and young children, but no vaccine exists to protect this vulnerable population. Furthermore, direct vaccination of neonates is likely ineffective due to the immaturity of their immune system, and neonate immunization is potentially unsafe. The current view is that maternal vaccination is the best and saf ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    SBC: SCARAB GENOMICS, LLC            Topic: NIAID

    Scarab Genomics has established a unique, tiny footprint, extended bacterial fermentation process enabled by its reduced genome E. coli, for production of protein therapeutics, especially vaccine conjugates. The process will massively reduce the cost and upgrade the quality of these critical vaccine components. This Phase IIB resubmission focuses on commercial development of Scarab’s first vacci ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government